American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification
Key Highlights
- ➤CHEST publishes six-step framework for standardized lung nodule program development
- ➤Framework recommends validated biomarkers, including Biodesix Nodify Lung tests, for risk stratification
- ➤Framework aims to reduce diagnostic delays and support earlier lung cancer detection
- ➤Biodesix CEO says physician consensus validates Nodify Lung’s clinical decision-making value
Expert Statements
Sonali Sethi, MD, FCCP Pulmonary Medicine, Cleveland, Ohio
“Guidelines have not kept pace with advances in nodule evaluation over the past 12 years.”
Sonali Sethi, MD, FCCP Pulmonary Medicine, Cleveland, Ohio
“This expert recommendation gives frontline clinicians a practical, systematic framework to move patients from nodule detection to diagnosis with greater consistency and confidence.”
Sonali Sethi, MD, FCCP Pulmonary Medicine, Cleveland, Ohio
“By standardizing risk assessment and incorporating validated tools, such as biomarkers, lung nodule programs can reduce delays, accelerate appropriate care, and improve the opportunity to diagnose lung cancer at an earlier, more treatable stage.”
Scott Hutton, CEO of Biodesix
“The inclusion of biomarker testing in this new framework is a significant validation of the clinical decision-making value of Nodify Lung testing.”
Scott Hutton, CEO of Biodesix
“Supported by the most mature and comprehensive body of peer-reviewed evidence in its category, Nodify Lung testing helps physicians risk-stratify patients with indeterminate pulmonary nodules.”
Scott Hutton, CEO of Biodesix
“Developed by leaders from some of the nation's most respected hospitals and health systems, this landmark physician consensus provides healthcare organizations with an evidence-based framework for building and optimizing lung nodule management programs.”
Scott Hutton, CEO of Biodesix
“It reflects the growing recognition that biomarker informed risk assessment can play an important role in improving diagnostic confidence, guiding clinical decisions, and advancing earlier detection of lung cancer.”
LOUISVILLE, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc (NASDAQ: BDSX), a leader in diagnostic solutions, today announced that the American College of Chest Physicians (CHEST) has published a new framework for clinical practice, “Building a Lung Nodule Program: From Detection to Diagnosis.” This groundbreaking framework describes six steps to building a comprehensive lung nodule program, with validated biomarker testing, such as the Biodesix Nodify Lung® tests, as a core component of standardizing risk stratification to guide clinical decisions.
The new CHEST framework was developed by a multidisciplinary panel of nationally recognized interventional pulmonologists, thoracic surgeons, and diagnostic radiologists representing leading hospitals and health systems throughout the United States. Drawing on published clinical evidence and real-world experience from established lung nodule programs, the panel defines a practical roadmap for building high performing programs that deliver consistent, evidence-based care and improve outcomes for patients with pulmonary nodules.
Get started
Create a free account to read the full story.